The latest product launches, like Secretome Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New product launches, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Launch Trends
See who's moving and how much in your market
No credit card required Weekly product launch digest
Secretome Therapeutics unveils patents for STM-01 and STM-21 to enhance their innovative medical therapies.
Oct 28, 2024•over 1 year ago
BaltimoreBiotechnology
Product Description
Secretome Therapeutics has announced the allowance of composition of matter patents for its lead cellular therapy asset STM-01 and its secretome product STM-21. These patents will bolster the company’s intellectual property and support their upcoming Phase 1 studies for STM-01.
Company Information
Company
Secretome Therapeutics
Location
323 W Camden St, Suite 600
Baltimore, Maryland, United States
About
Secretome Therapeutics is developing a platform of first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment and prevention of underserved diseases. Our lead product, STM-21, is a novel secretome in development for adult and pediatric forms of heart failure, and our pipeline includes novel secretomes in development for neurodegenerative and dermatological diseases.
BaltimoreBiotechnology